Stock RSPI RESPIRERX PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials RespireRx Pharmaceuticals Inc.

Equities

RSPI

US7612273059

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 19:26:13 14/05/2024 BST 		5-day change 1st Jan Change
0.00096 USD +1.05% Intraday chart for RespireRx Pharmaceuticals Inc. +11.11% +11.11%
04-10 RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding CI
03-20 RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 3.001 2.332 0.4045 2.067 1.127 0.2888
Enterprise Value (EV) 1 4.065 3.549 2.022 3.75 3.204 2.997
P/E ratio -0.64 x -0.84 x -0.18 x -0.13 x -0.29 x -0.06 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -0.96 x -1.63 x - - - -
EV / FCF 5.28 x -18 x 10.9 x -3.4 x -17.4 x 7.71 x
FCF Yield 19% -5.57% 9.14% -29.4% -5.75% 13%
Price to Book -0.8 x -0.44 x -0.06 x -0.26 x -0.11 x -0.02 x
Nbr of stocks (in thousands) 263 359 405 71,271 96,341 125,544
Reference price 2 11.40 6.500 0.9999 0.0290 0.0117 0.002300
Announcement Date 17/04/18 16/04/19 14/04/20 15/04/21 15/04/22 17/04/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -4.242 -2.171 - - - -
EBIT 1 -4.247 -2.177 -1.737 -3.315 -2.559 -1.579
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -4.291 -2.592 -2.115 -4.301 -3.145 -2.103
Net income 1 -4.291 -2.592 -2.115 -4.301 -3.145 -2.103
Net margin - - - - - -
EPS 2 -17.75 -7.734 -5.411 -0.2221 -0.0399 -0.0357
Free Cash Flow 1 0.7705 -0.1976 0.1848 -1.101 -0.1843 0.389
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 17/04/18 16/04/19 14/04/20 15/04/21 15/04/22 17/04/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 1.06 1.22 1.62 1.68 2.08 2.71
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.2508 x -0.5603 x - - - -
Free Cash Flow 1 0.77 -0.2 0.18 -1.1 -0.18 0.39
ROE (net income / shareholders' equity) 87.1% 51.4% 32.1% 55.5% 34.8% 19.2%
ROA (Net income/ Total Assets) -1,239% -853% -1,280% -3,178% -1,089% -853%
Assets 1 0.3465 0.3039 0.1652 0.1354 0.2889 0.2466
Book Value Per Share 2 -14.30 -14.90 -17.90 -0.1100 -0.1000 -0.0900
Cash Flow per Share 2 0.2800 0.0900 0.0400 0 0 -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 17/04/18 16/04/19 14/04/20 15/04/21 15/04/22 17/04/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RESPIRERX PHARMACEUTICALS INC. Stock RespireRx Pharmaceuticals Inc.
+11.11% 744K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.33% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.11% 106B
BIONTECH SE Stock BioNTech SE
-12.56% 22.24B
ARGENX SE Stock argenx SE
-3.49% 21.25B
GENMAB A/S Stock Genmab A/S
-5.94% 18.97B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.86% 16.81B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.57% 12.54B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-26.24% 8.09B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RSPI Stock
  4. Financials RespireRx Pharmaceuticals Inc.